Definium Therapeutics, Inc. (DFTX)
36.73
-0.92
(-2.44%)
USD |
NASDAQ |
Sep 24, 16:00
37.04
+0.31
(+0.84%)
Pre-Market: 09:19
Definium Therapeutics Research and Development Expense (Quarterly) : 48.66M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 48.66M |
| March 31, 2026 | 41.48M |
| December 31, 2025 | 33.52M |
| September 30, 2025 | 30.98M |
| June 30, 2025 | 29.81M |
| March 31, 2025 | 23.36M |
| December 31, 2024 | 21.76M |
| September 30, 2024 | 17.19M |
| June 30, 2024 | 14.64M |
| March 31, 2024 | 11.18M |
| December 31, 2023 | 10.76M |
| September 30, 2023 | 12.40M |
| June 30, 2023 | 13.98M |
| March 31, 2023 | 11.81M |
| December 31, 2022 | 8.04M |
| September 30, 2022 | 6.972M |
| June 30, 2022 | 8.526M |
| March 31, 2022 | 9.461M |
| Date | Value |
|---|---|
| December 31, 2021 | 17.29M |
| September 30, 2021 | 8.219M |
| June 30, 2021 | 7.274M |
| March 31, 2021 | 5.759M |
| December 31, 2020 | 4.912M |
| September 30, 2020 | 5.342M |
| June 30, 2020 | 2.700M |
| March 31, 2020 | 1.804M |
| August 31, 2019 | |
| May 31, 2019 | |
| February 28, 2019 | |
| November 30, 2018 | |
| August 31, 2018 | |
| May 31, 2018 | |
| February 28, 2018 | |
| November 30, 2017 | |
| August 31, 2017 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Enliven Therapeutics, Inc. | 28.99M |
| Cocrystal Pharma, Inc. | 2.142M |
| CNBX Pharmaceuticals, Inc. | -- |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 52.30M |